Business
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or chemotherapy Expected readouts for Phase 1b trial in p53-mutated non-small cell lung cancer (NSCLC): Interim data in 2Q22; topline results in 4Q22Anticipated milestones for planned Phase 1b clinical trial in p53-mutated neoadjuvant breast cancer: Initiation in 1H22; interim results in 4Q22 Cash, cash equivalents and investments as of December 31, 2021 expected to fund operations into the fourth quarter of 2023 BOSTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021. “We’re incredibly proud of the progress we’ve made to date advancing our mission to develop a targeted drug that prevents chemotherapy-induced side effects in patients with p53-mutated cancer,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer of Aileron Therapeutics. “Given proof of concept of ALRN-6924’s ability to protect against chemotherapy-induced bone marrow toxicities and its potential to also protect against multiple other chemotherapy-induced toxicities, our vision is to redefine care for millions of cancer patients, regardless of the type of p53-mutated cancer they have or the type of chemotherapy they receive. We look forward to several anticipated catalysts in 2022 that could further propel us toward this vision.” Aileron is developing ALRN-6924 to protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced side effects. Nearly 1 million patients each year are diagnosed with a p53-mutated cancer in the US alone, and Aileron is pioneering a precision medicine-based approach known as selective chemoprotection to exclusively treat patients with p53-mutated cancers who are receiving chemotherapy. ALRN-6924 is designed to selectively protect these patients’ healthy cells from chemotherapy without interfering with chemotherapy’s effects on cancer cells. The reduction or elimination of multiple chemotherapy-induced side effects is expec...